SCHEMBL5572178

SCHEMBL5572178

CC(=O)[C@H]1[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.67
SHBG P04278 8/20 0.67
SMN1; SMN2 Q16637 7/20 0.67
SERPINA6 P08185 7/20 0.67
CYP3A4 P08684 6/20 0.67
MAPK1 P28482 6/20 0.67
ALDH1A1 P00352 6/20 0.67
TSHR P16473 5/20 0.67
MAPT P10636 5/20 0.67
NR3C1 P04150 4/20 0.67
PGR P06401 3/20 0.67
AR P10275 3/20 0.67
GPBAR1 Q8TDU6 3/20 0.67
SIGMAR1 Q99720 3/20 0.67
PMP22 Q01453 3/20 0.67
NPSR1 Q6W5P4 3/20 0.67
CYP2C9 P11712 2/20 0.67
HIF1A Q16665 2/20 0.67
CYP2C19 P33261 2/20 0.67
MEN1 O00255 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL601152 1.00 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL601153 1.00 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11766174 0.89 SHBG (0.64) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11766184 0.89 SHBG (0.64) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL572119 0.89 SHBG (0.77) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11544123 0.89 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL638332 0.89 SHBG (0.77) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11544128 0.89 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL9242740 0.88 SHBG (0.63) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL8781737 0.88 LMNA (0.69) LMNASHBGSMN1; SMN2SERPINA6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070014719-A1 Steroid analogs and characterization and treatment methods BIOVIE INC. 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014719-A1 Steroid analogs and characterization and treatment methods CYP17A1, HSD17B11, HSD3B1 LMNA 2328/4885SHBG 40/4885SMN1; SMN2 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.